Cargando…

Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: a phase I study

Conventional treatment for brain metastases (BM) is whole-brain radiotherapy (WBRT). Efficacy is poor. It might be increased by a potent radiosensitiser such as gemcitabine which is believed to cross the disrupted blood–brain barrier. Primary objective of this study was to determine the maximum tole...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maraveyas, A, Sgouros, J, Upadhyay, S, Abdel-Hamid, A-H, Holmes, M, Lind, M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2005
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361913/ https://www.ncbi.nlm.nih.gov/pubmed/15714201 http://dx.doi.org/10.1038/sj.bjc.6602444

Ejemplares similares

The role of apoptotic cell death in the radiosensitising effect of gemcitabine
por: Pauwels, B, et al.
Publicado: (2009)

Cyclopentenyl cytosine increases gemcitabine radiosensitisation in human pancreatic cancer cells
por: van Bree, C, et al.
Publicado: (2008)

An evaluation of gemcitabines differential radiosensitising effect in related bladder cancer cell lines
por: Sangar, V K, et al.
Publicado: (2004)

Phase I Trial of Radiotherapy Concurrent with Twice-Weekly Gemcitabine for Head and Neck Cancer: Translation From Preclinical Investigations Aiming to Improve the Therapeutic Ratio()()
por: Popovtzer, Aron, et al.
Publicado: (2014)

Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers
por: Harrington, K J, et al.
Publicado: (2011)

Cytotoxic and radiosensitising effects of a novel thioredoxin reductase inhibitor in breast cancer
por: Abdullah, Nurul A, et al.
Publicado: (2021)

Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
por: Kim, R D, et al.
Publicado: (2018)

Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study
por: Sugimoto, T., et al.
Publicado: (2019)

The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines
por: Pauwels, Bea, et al.
Publicado: (2006)

B-type natriuretic peptide levels and volume status in twice-weekly hemodialysis patients
por: Fang, Nina, et al.
Publicado: (2021)

Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations
por: Azzabi, A, et al.
Publicado: (2005)

Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer
por: Nakamura, K, et al.
Publicado: (2005)

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
por: Demols, A, et al.
Publicado: (2006)

Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients
por: Corrie, P G, et al.
Publicado: (2005)

Is Twice-weekly Maintenance Hemodialysis Justified?
por: Mendonca, Satish, et al.
Publicado: (2021)

A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer
por: Michael, M, et al.
Publicado: (2009)

Radiosensitisation of Hepatocellular Carcinoma Cells by Vandetanib
por: Znati, Sami, et al.
Publicado: (2020)

Phase I study of gemcitabine using a once every 2 weeks schedule.
por: Vermorken, J. B., et al.
Publicado: (1997)

Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study
por: Michaelson, M D, et al.
Publicado: (2013)

Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer
por: van der Noll, R., et al.
Publicado: (2015)

Efficacy of once-weekly and twice-weekly injections of teriparatide by patient characteristics: A post hoc analysis of the TWICE study
por: Sugimoto, Toshitsugu, et al.
Publicado: (2021)

Comparison of twice weekly palliative RT versus continuous hypofractionated palliative RT for painful bone metastases
por: Bandyopadhyay, Anis, et al.
Publicado: (2023)

Design, Synthesis and Anticancer Evaluation of Nitroimidazole Radiosensitisers
por: Liew, Lydia P., et al.
Publicado: (2023)

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies
por: Bringhen, Sara, et al.
Publicado: (2019)

Comparison of different dosing regimens (once weekly vs. twice weekly, and once weekly vs. once every two weeks) with epoetin delta in patients with chronic kidney disease: a randomized controlled trial
por: Macdougall, Iain C
Publicado: (2007)

A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer
por: Ikeda, M, et al.
Publicado: (2002)

Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study
por: Valle, J W, et al.
Publicado: (2009)

Feasibility of Twice-Weekly Hemodialysis: Contingency Planning for COVID-19
por: Clark, David A., et al.
Publicado: (2021)

Metformin is a metabolic modulator and radiosensitiser in rectal cancer
por: Buckley, Croí E., et al.
Publicado: (2023)

Frequency and change mechanisms of psychotherapy among depressed patients: study protocol for a multicenter randomized trial comparing twice-weekly versus once-weekly sessions of CBT and IPT
por: Bruijniks, Sanne J. E., et al.
Publicado: (2015)

The role of mitochondrial function in gold nanoparticle mediated radiosensitisation
por: Taggart, Laura E, et al.
Publicado: (2014)

Feasibility of Twice-Weekly Hemodialysis During COVID-19
por: Siga, Esteban
Publicado: (2021)

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial
por: Yardley, Denise A., et al.
Publicado: (2015)

A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma
por: Veldhuijzen van Zanten, Sophie E. M., et al.
Publicado: (2017)

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts
por: Nadeem, Omar, et al.
Publicado: (2020)

Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies
por: Tan, A R, et al.
Publicado: (2014)

A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer
por: Hoff, P M, et al.
Publicado: (2008)

Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study
por: López-Pousa, A, et al.
Publicado: (2006)

Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra®, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours
por: Siegel-Lakhai, W S, et al.
Publicado: (2005)

Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
por: Heinrich, Stefan, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_nvdbtfp167cme5651l4eqqlaip